I’ve been watching this stock for awhile. It was the “darling” stock before the market crash in Feb and it dropped a whole lot from its ATH.
I think it shows some promise in terms of market reach due to changing its model to a “rental” model so most labs don’t need to outright buy the Saphry system. However, I’ve read that most hospitals and bigger reasearch labs are unlikely to adopt it since it has far less use cases than Pacific Biosciences gene sequencing system.
Keeping my fingers crossed it will see more uptake going forward
Sorry, this post has been deleted
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments